Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial
Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).